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PARACOCCIDIOIDOMYCOSIS: ADVANCES AND UNMET NEEDS 100 YEARS 
AFTER ITS INITIAL DESCRIPTION BY LUTZ 
 
Initially described by Adolfo Lutz in 1908, paracoccidioiodomycosis (PCM) is 
considered to be the most prevalent endemic systemic mycosis in Brazil and other 
Latin American countries. Based on data generated by epidemiological surveys 
employing intradermal tests for paracoccidioidin, the prevalence of Paracoccidioides 
brasiliensis infection in these endemic areas may be as high as 50% to 75% among 
the adult population, and almost 10 million people may have been infected by this 
pathogen (1, 21). 
One hundred years after the original description of PCM, we may celebrate several 
instances of substantial progress in characterizing P. brasiliensis. These advances 
include the complete sequencing of its genome, the evaluation of molecular factors 
that trigger the transition from hyphal to yeast form, the determination of the most 
relevant virulence factors as well as the importance of the glycoprotein gp43 in terms 
of fungal pathogenesis and mediating host-immune response. In addition, several 
well-conducted studies have consistently characterized the cell-mediated immune 
mechanisms needed to contain P. brasiliensis infection. In this regard, Type 1 (Th1) 
response, with high levels of IFN-γ and IL-2, has been related to immunity in animal 
and human models of the disease. On the other hand, susceptibility is linked to Type 
2 (Th2) response, and production of IL-4, IL-5, IL-10 and TGF-ß (2, 4, 8, 11, 13, 14, 
17, 19). 
In terms of diagnosis, the advances are also remarkable since today we have 
available both several sensitive and specific methods for detecting anti-P. brasiliensis 
antibodies and ELISA assays for detecting specific antigens of the fungus in different 
biological fluids. Different polymerase chain reaction-based methods exist not only 
for identifying PCM, but also for genotyping P. brasiliensis isolates (4, 7, 9, 12, 16, 
21). 
Antifungal treatment of patients with paracoccidioidomycosis is still controversial. The 
few studies available on antifungal treatment of PCM enrolled a limited number of 
patients, and were neither randomized nor statistically robust (18, 21). Thus, they did 
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not permit consistent conclusions about comparative efficacy analysis. Considering 
the limited data generated by well-conducted clinical trials in PCM, most guidelines 
for treating patients with this fungal infection are strongly based on expert opinions 
(18). 
Long-term therapy consisting mostly of itraconazole or the combination of 
trimethoprim and sulfamethoxazole is usually required to achieve good clinical 
response and avoid relapses that are clearly correlated with drug toxicity, high costs 
and abandonment of treatment by patients (1, 18, 21). Recently, Queiroz-Telles et al. 
(15) demonstrated that although voriconazole is a safe alternative therapy for 
patients with PCM, it still requires long periods of treatment.   
Besides the long periods of antifungal therapy required by these patients, relapses 
remain a significant problem in clinics. The non-responsive severely ill patients 
represent an unsolved problem for the conventional therapeutic approach. Patients 
who receive antifungal therapy but do not develop a stable Th1 response against the 
fungal pathogen are more prone to relapse (1, 18, 21).  
Despite all scientific progress towards the characterization of P. brasiliensis and its 
pathogenesis in animal and human models, as well as the standardization of 
sensitive laboratory tests to diagnose PCM, this endemic mycosis remains a major 
cause of disability and death among rural young adult workers during their most 
productive years of life. This phenomenon is partially related to the social and 
economic status of the target population for this disease, mostly represented by rural 
workers with low incomes and limited access to a public or private health system. It is 
important to mention that limited economic resources may impair the host response 
to fungal infection and hinder the early detection of infected patients by the health 
care system. Consequently, at the time most patients are diagnosed with fungal 
infection, they are already severely ill with multiple organs compromised by the 
disease (21). 
There is a consensus that respiratory failure and adrenal insufficiency are two of the 
most commonly reported sequelae among adult patients who develop PCM. A study 
carried out by Tobón et al. (20) documented lung sequelae among 47 adult patients 
with PCM treated with itraconazole. Fibrosis was observed in 31.8% of the patients at 
diagnosis and had not cleared at the end of the observation period in any of these 
patients. After starting treatment, some of the others patients also developed fibrosis 
and by the end of the follow-up period the disease was detected in 53.2% of patients 
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overall. Adrenal dysfunction secondary to PCM may be detected in 10% to 44% of 
patients evaluated by different functional tests, including evaluation of cortisol 
synthesis by infusion of Cortrosyn® (exogenous adrenocorticotropic hormone). 
Symptomatic adrenal dysfunction has been reported in 3% to 6% of patients (5). 
Based on data obtained from the Brazilian Health Ministry´s Mortality Information 
System, a total of 3,181 PCM deaths were reported in Brazil between 1980 and 
1995, corresponding to a mortality rate of 1.45 deaths per million inhabitants (6). A 
recent publication using the same mentioned death registry data attempted to 
exclusively evaluate the mortality rate of PCM reported in the state of Parana, an 
area highly endemic for this fungal infection, in which the average PCM mortality rate 
was 3.48 per million inhabitants, ranking this fungal infection as the fifth most 
common cause of death among all chronic infections with high prevalence in that 
particular region (3).  
In conclusion, it is possible to suggest that the scientific community may celebrate 
several relevant contributions obtained in the study of this pathogen´s biology, 
mechanisms of infection and host-response. New sensitive and specific diagnostic 
tools were developed but, unfortunately, they were not incorporated into the routine 
of most public medical centers due to cost issues and lack of human resources 
trained in medical mycology. New efforts are necessary to enable early diagnosis of 
paracoccidioidomycosis and to develop alternative therapeutic strategies against the 
fungus to improve patient compliance and final efficiency of the regimens (21). 
Recently, Travassos and colleagues (21) have demonstrated that a peptide-based 
vaccine may induce a Th1 response in Balb/c mice infected by P. brasiliensis, 
resulting in a significant reduction in the fungal load. This finding suggests that in the 
future we may have patients treated by immune stimulation with peptide vaccine as 
an adjuvant to antifungal drugs in order to shorten the treatment period of and 
decrease the number of relapses and sequels (10, 21).  
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